News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
Quant’s Rally Draws Attention As Bulls Eye $103 Liquidity Zone
Quant’s 6% rally sparks bullish interest as traders target the $103 liquidity zone. Rising open interest and CMF strength back the case for more upside.
BeInCrypto·2025/09/27 23:41
Bitcoin News: Will BTC Price Crash to $81,000?
Bitcoin is sliding towards a key support level as inflation rises and the Federal Reserve remains hesitant about cutting interest rates.
Cryptoticker·2025/09/27 22:53
Altcoins Lead Q3 2025 Crypto Performance, Outpacing Bitcoin
Cryptotale·2025/09/27 22:00
XRP Approaches $3 Amid Vanguard ETF Shift
TheCryptoUpdates·2025/09/27 21:39
Ethereum price drops 20% as liquidations near $1 billion
TheCryptoUpdates·2025/09/27 21:39
Grayscale Near Trust begins trading on OTCQB under ticker GSNR
TheCryptoUpdates·2025/09/27 21:39
Ethereum falls below $4,000 amid BlackRock sales and ETF outflows
TheCryptoUpdates·2025/09/27 21:39
Panoramic Comparison of 14 Perp DEXs: Who Will Be the Next Hyperliquid?
For retail investors, for projects that have not yet had a TGE, you can interact with a few of them to earn points; for projects that have already had a TGE, it's best to consider both market cap and trend, and ideally buy on the right side.
深潮·2025/09/27 21:18
Fidelity Sells $300M in BTC, Latest Whale Data Confirms Move
coinfomania·2025/09/27 20:57
Bitcoin Shows Bull Flag Potential, $114.5K FVG Validated by Market Data
coinfomania·2025/09/27 20:57
Flash
12:56
Spot Gold Drops $14 in Short-Term Spot gold has fallen $14 in the short term, declining over 1.00% during the day, currently reported at $4133.10 per ounce. (Jin Shi)
12:52
Splash Beverage Group Inc. has successfully secured a $1 million strategic investment from C/M Capital Partners.This funding will be specifically allocated for the development of its Cannepil project.
12:51
Vivos (OTC market code: RDGL) has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) and will initiate a human clinical feasibility study of its Radiogel® Precision Radionuclide Therapy™.This approval marks a key step forward for the clinical application of this innovative therapy, allowing the company to begin initial safety and feasibility assessments in humans. The Radiogel® technology is designed to enable precise radiation treatment within tumors and is expected to provide a new treatment option for cancer patients. The approved clinical study will collect essential data to lay the foundation for larger-scale clinical trials in the future.
News